Ph IIA Study (SOC +/- NS5B)

NCT01193361 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: BMS-791325
DRUG: BMS-791325
DRUG: Placebo
DRUG: Peg-interferon alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb